Brussels, 19 September 2016
The European Biopharmaceutical Enterprises (EBE) today published a White Paper that scrutinises funding available for innovative biopharmaceutical entrepreneurs in Europe and explores why fewer successful businesses are built in Europe – despite our exceptional science – than in other world regions.
While welcoming the funding opportunities available in Europe, EBE has identified a number of funding related and non-funding related factors, which continue to impede corporate development in Biopharma.
Specifically, EBE calls for actions aimed at:
— improving entrepreneurial awareness at European universities;
— increased funding of European cross-over investors and large venture capital funds; and
— facilitating a single capital market for biotechnology companies in Europe and boosting incentives – including tax incentives – for investing in European biotech.
“Europe continues to harbour outstanding science and rightly invests solidly in research and innovation,” said Barbara Freischem, Executive Director of EBE. “We must now adopt a collaborative approach with the relevant stakeholders to ensure that this science translates into successful new businesses.”
The EBE White Paper: “Europe’s flawed and underfunded Biotech-ecosystem”, is available here.
The European Biopharmaceutical Enterprises (EBE), a specialised group of the European Federation of Pharmaceutical Industries and Associations (EFPIA), is the European trade association that represents biopharmaceutical companies of all sizes operating in Europe. It has more than 50 member companies - the majority of which are small and medium sized companies - engaged in the research, development, manufacturing and marketing of new medicinal products using biotechnology.
More information on EBE is available on the EBE website at http://ebe-biopharma.eu/.
Executive Director, European Biopharmaceutical Enterprises
+32 2 626 25 64